175 related articles for article (PubMed ID: 27756545)
1. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Alibhai SM; Aziz S; Manokumar T; Timilshina N; Breunis H
J Geriatr Oncol; 2017 Jan; 8(1):31-36. PubMed ID: 27756545
[TBL] [Abstract][Full Text] [Related]
2. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.
Moth EB; Kiely BE; Stefanic N; Naganathan V; Martin A; Grimison P; Stockler MR; Beale P; Blinman P
J Geriatr Oncol; 2019 Mar; 10(2):202-209. PubMed ID: 30224184
[TBL] [Abstract][Full Text] [Related]
3. Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
Alibhai SMH; Breunis H; Hansen AR; Gregg R; Warde P; Timilshina N; Tomlinson G; Joshua AM; Hotte S; Fleshner N; Emmenegger U
Cancer; 2021 Jul; 127(14):2587-2594. PubMed ID: 33798267
[TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer.
Cavdar E; Iriagac Y; Karaboyun K; Avci O; Seber ES
J Geriatr Oncol; 2022 Jul; 13(6):821-827. PubMed ID: 35361561
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
6. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
[TBL] [Abstract][Full Text] [Related]
7. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
Kongsted P; Svane IM; Lindberg H; Daugaard G; Sengeløv L
Urol Oncol; 2015 Nov; 33(11):494.e15-20. PubMed ID: 26254696
[TBL] [Abstract][Full Text] [Related]
8. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
11. The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
Kim VS; Yang H; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen AR; Tomlinson G; Alibhai SMH
J Geriatr Oncol; 2023 Mar; 14(2):101417. PubMed ID: 36682218
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
13. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
14. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
16. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Martini A; Parikh AB; Sfakianos JP; Montorsi F; Galsky MD; Oh WK; Tsao CK
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):743-749. PubMed ID: 33531652
[TBL] [Abstract][Full Text] [Related]
17. Utility of a chemotherapy toxicity prediction tool for older patients in a community setting.
Mariano C; Jamal R; Bains P; Hejazi S; Chao L; Wan J; Ho J
Curr Oncol; 2019 Aug; 26(4):234-239. PubMed ID: 31548802
[TBL] [Abstract][Full Text] [Related]
18. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13).
Luciani A; Biganzoli L; Colloca G; Falci C; Castagneto B; Floriani I; Battisti N; Dottorini L; Ferrari D; Fiduccia P; Zafarana E; Del Monte F; Galli F; Monfardini S; Foa P
J Geriatr Oncol; 2015 Jul; 6(4):272-9. PubMed ID: 26088748
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
20. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
